Treatment Effects of Bisoprolol and Verapamil in Symptomatic Patients With Non-obstructive Hypertrophic Cardiomyopathy

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 100 participants.

Also called NCT05569382

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05569382
  • EudraCT 2021-006953-77
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Denmark (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05569382. Randomized; triple masking; primary purpose treatment. Start 2022-08-10 (actual); primary completion 2027-04-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Treatment Effects of Bisoprolol and Verapamil in Symptomatic Patients With Non-obstructive Hypertrophic Cardiomyopathy
Acronym
TEMPO II
Condition
Non-obstructive Hypertrophic Cardiomyopathy
Intervention (Drug)
Verapamil
Intervention (Drug)
Bisoprolol
Intervention (Drug)
Placebo
Lead sponsor
Morten Steen Kvistholm Jensen (class: other)
Collaborator
Viborg Regional Hospital (class: other)
Collaborator
Zealand University Hospital (class: other)
Collaborator
Odense University Hospital (class: other)

Record details

Record id
cardio:ct-nct05569382
Content hash
497f70edd5034f091cc911d3493c845f76e220b14f3f733965442c80e0d99fa7